Introducing pro and con discussions in ESMO Open—Cancer Horizons

por Zielinski, C., Preusser, M., Berghoff, A.
Publicado 2022

Macrophage and monocyte subsets as new therapeutic targets in cancer immunotherapy

por Fendl, B., Berghoff, A.S., Preusser, M., Maier, B.
Publicado 2023

Expectations and perception of cancer treatment goals in previously untreated patients. The EXPECT trial

por Minichsdorfer, Christoph, Zeller, O., Kirschbaum, M., Berghoff, A. S., Bartsch, R.
Publicado 2020

Pityriasis rubra pilaris nach COVID-19-Impfung: Kausaler Zusammenhang oder Koinzidenz?

por Bramhoff, A. C., Wesselmann, U., Bender, S. T., Berghoff, A. V., Hofmann, S. C., Balakirski, G.
Publicado 2022

Elevated Free Thyroxine Levels Are Associated with Poorer Overall Survival in Patients with Gastroesophageal Cancer: A Retrospective Single Center Analysis

por Puhr, H. C., Wolf, P., Berghoff, A. S., Schoppmann, S. F., Preusser, M., Ilhan-Mutlu, Aysegul
Publicado 2019

Next-Generation Sequencing-based genomic profiling of brain metastases of primary ovarian cancer identifies high number of BRCA-mutations

por Balendran, S., Liebmann-Reindl, S., Berghoff, A. S., Reischer, T., Popitsch, N., Geier, C. B., Kenner, L., Birner, P., Streubel, B., Preusser, M.
Publicado 2017

Primary tumor side is associated with prognosis of colorectal cancer patients with brain metastases

por Bergen, E.S., Scherleitner, P., Ferreira, P., Kiesel, B., Müller, C., Widhalm, G., Dieckmann, K., Prager, G., Preusser, M., Berghoff, A.S.
Publicado 2021

Brain metastases as first manifestation of advanced cancer: exploratory analysis of 459 patients at a tertiary care center

por Füreder, L. M., Widhalm, G., Gatterbauer, B., Dieckmann, K., Hainfellner, J. A., Bartsch, R., Zielinski, C. C., Preusser, M., Berghoff, A. S.
Publicado 2018

Clinical risk factors for ascites in metastatic pancreatic cancer

por Berger, J.M., Alany, A., Puhr, R., Berchtold, L., Friedrich, A., Scheiner, B., Prager, G.W., Berghoff, A.S., Preusser, M., Bergen, E.S.
Publicado 2023

Brain-only metastatic breast cancer is a distinct clinical entity characterised by favourable median overall survival time and a high rate of long-term survivors

por Berghoff, A S, Bago-Horvath, Z, Ilhan-Mutlu, A, Magerle, M, Dieckmann, K, Marosi, C, Birner, P, Widhalm, G, Steger, G G, Zielinski, C C, Bartsch, R, Preusser, M
Publicado 2012

Tumor mutational burden and immune infiltrates in renal cell carcinoma and matched brain metastases

por Steindl, A., Alpar, D., Heller, G., Mair, M.J., Gatterbauer, B., Dieckmann, K., Widhalm, G., Hainfellner, J.A., Schmidinger, M., Bock, C., Müllauer, L., Preusser, M., Berghoff, A.S.
Publicado 2021

Development of an alarm symptom-based risk prediction score for localized oesophagogastric adenocarcinoma (VIOLA score)

por Puhr, H.C., Puhr, R., Kuchling, D.A., Jahic, L., Takats, J., Reiter, T.J., Paireder, M., Jomrich, G., Schoppmann, S.F., Berghoff, A.S., Preusser, M., Ilhan-Mutlu, A.
Publicado 2022

Prognostic impact of breast cancer subtypes in elderly patients

por Bergen, E. S., Tichy, C., Berghoff, A. S., Rudas, M., Dubsky, P., Bago-Horvath, Z., Mader, R. M., Exner, R., Gnant, M., Zielinski, C. C., Steger, G. G., Preusser, M., Bartsch, R.
Publicado 2016

1692P SARS-CoV-2 RNA testing in cancer patients treated at a Department of Medical Oncology in Vienna, Austria

por Berghoff, A.S., Gansterer, M., Bathke, A.C., Trutschnig, W., Hungerländer, P., Berger, J.M., Kreminger, J., Starzer, A., Schmidt, R., Lamm, W., Raderer, M., Gottlieb, A.D., Mauser, N.J., Preusser, M.
Publicado 2020

Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases

por Bartsch, R, Berghoff, A, Pluschnig, U, Bago-Horvath, Z, Dubsky, P, Rottenfusser, A, DeVries, C, Rudas, M, Fitzal, F, Dieckmann, K, Mader, R M, Gnant, M, Zielinski, C C, Steger, G G
Publicado 2012

Brain metastases free survival differs between breast cancer subtypes

por Berghoff, A, Bago-Horvath, Z, De Vries, C, Dubsky, P, Pluschnig, U, Rudas, M, Rottenfusser, A, Knauer, M, Eiter, H, Fitzal, F, Dieckmann, K, Mader, R M, Gnant, M, Zielinski, C C, Steger, G G, Preusser, M, Bartsch, R
Publicado 2012

Has COVID-19 had a greater impact on female than male oncologists? Results of the ESMO Women for Oncology (W4O) Survey

por Garrido, P., Adjei, A.A., Bajpai, J., Banerjee, S., Berghoff, A.S., Choo, S.P., Felip, E., Furness, A.J.S., Garralda, E., Haanen, J., Letsch, A., Linardou, H., Peters, S., Sessa, C., Tabernero, J., Tsang, J., Yang, J.C-.H., Garassino, M.C.
Publicado 2021

Female leadership in oncology—has progress stalled? Data from the ESMO W4O authorship and monitoring studies

por Berghoff, A.S., Sessa, C., Yang, J.C.-H., Tsourti, Z., Tsang, J., Tabernero, J., Peters, S., Linardou, H., Letsch, A., Haanen, J., Garralda, E., Garassino, M.C., Furness, A.J.S., Felip, E., Dimopoulou, G., Dafni, U., Choo, S.P., Banerjee, S., Bajpai, J., Adjei, A.A., Garrido, P.
Publicado 2021

Challenges in oncology career: are we closing the gender gap? Results of the new ESMO Women for Oncology Committee survey

por Linardou, H., Adjei, A.A., Bajpai, J., Banerjee, S., Berghoff, A.S., Mathias, C. Cerqueira, Choo, S.P., Dent, R., Felip, E., Furness, A.J.S., Garassino, M.C., Garralda, E., Konsoulova-Kirova, A., Letsch, A., Menzies, A.M., Mukherji, D., Peters, S., Sessa, C., Tsang, J., Yang, J.C.-H., Garrido, P.
Publicado 2023

Young oncologists’ perspective on the role and future of the clinician-scientist in oncology

por Lim, K.H.J., Westphalen, C.B., Berghoff, A.S., Cardone, C., Connolly, E.A., Güven, D.C., Kfoury, M., Kocakavuk, E., Mandó, P., Mariamidze, E., Matikas, A., Moutafi, M., Oing, C., Pihlak, R., Punie, K., Sánchez-Bayona, R., Sobczuk, P., Starzer, A.M., Tečić Vuger, A., Zhu, H., Cruz-Ordinario, M.V.B., Altuna, S.C., Canário, R., Vuylsteke, P., Banerjee, S., de Azambuja, E., Cervantes, A., Lambertini, M., Mateo, J., Amaral, T.
Publicado 2023